Zimbabwe has turned down a major US health deal worth 367 million US dollars (272 million pounds) over five years over the United States' demand for confidential data.
The decision was revealed following a government memo from December was disclosed, which showed President Emmerson Mnangagwa believed the deal was "unbalanced".
An official spokesperson later stated that the United States was requesting biological samples for research and commercial gain but was not willing to guarantee the resulting advantages from future vaccines.
"We will now turn to the challenging and unfortunate task of winding down our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy indicated the United States had donated more than $1.9bn as health assistance to Zimbabwe over the last two decades.
A physicians' group in Zimbabwe has called for more negotiations to secure a deal suitable to both sides so the nation's vital HIV programme can proceed.
Broader Background
Zimbabwe's decision follows a similar situation in neighbouring Kenya, where a court suspended a related health funding agreement following legal challenges were raised about the safety of citizens' health data.
After resuming office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had managed aid for the American government, but Trump stated its expenditure was "inefficient" and his government was seeking direct bilateral agreements to enhance openness and accountability.
As per reports, 16 African countries have to date agreed to similar agreements, representing more than $18.3bn in new funding.
Details of the Declined Agreement
The money for Zimbabwe would have gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this partnership would have delivered extraordinary advantages for the people of Zimbabwe, especially the 1.2 million presently receiving antiretroviral therapy through US-supported programmes," Tremont commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "asymmetrical".
"Zimbabwe was being asked to share its biological resources and data over an extended period, without any equivalent promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that might be developed from that provided information," his statement read.
"In essence, our country would supply the raw materials for medical research without any certainty that the resulting innovations would be accessible to our population if a future health crisis emerge."
National Interest and International Frameworks
Mangwana further said that the US's withdrawal from the global health body and its push of bilateral deals were undermining systems previously set up through the global health agency.
Mangwana cited its Pathogen Access and Benefit Sharing framework created to manage future global health emergencies.
"This system is designed to ensure that when a country contributes its samples, the benefits – such as medicines and cures – are distributed fairly, not monopolised exclusively by those with the resources to develop them."
The government's concerns over the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We welcome continued discussions with our US partners on how subsequent co-operation might be structured in a way that respects the sovereignty and interests of each country."
Medical Community Reaction
Medical experts said it acknowledged the official position, but urged that talks should continue given that a large portion of the country's Aids initiatives relied on foreign aid.
"If specific concerns exist, such as those involving data governance or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," it commented.
The situation emphasises the complex challenges between accepting vital foreign assistance and protecting national sovereignty in an ever more interconnected world.